FDA Warning Letter — Raritan Pharmaceuticals, Inc.
The FDA took a Warning Letter action against Raritan Pharmaceuticals, Inc. on Jun 20, 2017 (East Brunswick, NJ). The action was issued by CDER and concerns drugs products. This facility has 5 or more recent FDA inspections on record.
Action Details
- Facility
- Raritan Pharmaceuticals, Inc.
- Date
- Jun 20, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Center
- CDER
- Location
- East Brunswick, NJ (United States)